BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D; le GETAID. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflamm Bowel Dis 2016;22:1362-9. [PMID: 26919458 DOI: 10.1097/MIB.0000000000000741] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. Front Oncol 2020;10:584. [PMID: 32391269 DOI: 10.3389/fonc.2020.00584] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
2 Phan H, Weideman RA, Cipher DJ, Feagins LA. Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy. Intest Res 2020;18:282-8. [PMID: 32252501 DOI: 10.5217/ir.2019.09140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016;151:97-109.e4. [PMID: 27039969 DOI: 10.1053/j.gastro.2016.03.037] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
4 Mizoshita T, Ando M, Sagawa H, Mori Y, Katano T, Ozeki K, Tanida S, Okamoto Y, Shimura T, Kubota E, Kataoka H, Kamiya T, Joh T. Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy. Clin J Gastroenterol 2017;10:250-4. [PMID: 28271435 DOI: 10.1007/s12328-017-0726-3] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol 2019;12:1756284818817293. [PMID: 30643542 DOI: 10.1177/1756284818817293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ueda T, Tanaka T, Yokoyama T, Sadamitsu T, Koyama F, Fujii H, Yoshimura A. Long-Term Survival After Pelvic Exenteration for Locally Recurrent Rectal Cancer Associated With Crohn's Disease With, Adjuvant Chemotherapy, and Immunosuppressive Therapy. ACG Case Rep J 2020;7:e00374. [PMID: 32548201 DOI: 10.14309/crj.0000000000000374] [Reference Citation Analysis]